| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
Purity: ≥98%
GSK2200150A is a novel and potent antimycobacterial agent that has the potential for the treatment of tuberculosis (TB). It has activity against Mycobacterium tuberculosis and Mycobacterium bovis BCG. Tuberculosis afflicts an estimated 2 billion people worldwide and causes 1.3 million deaths annually. Chemotherapeutic solutions rely on drugs developed many years ago, with only one new therapeutic having been approved in the last 40 years. Given the rise of drug-resistant strains, there is an urgent need for the development of a more robust drug development pipeline.
| Targets |
M.tuberculosis strain H37Rv（MIC=0.38 μM）
GSK2200150A acts on the target MmpL3 (Mycobacterium tuberculosis membrane protein large 3), a key protein involved in the transport of mycobacterial cell wall lipids; [1] |
|---|---|
| ln Vitro |
A brand-new antimycobacterial drug called GSK2200150A works against Mycobacterium tuberculosis.With a minimum inhibitory concentration (MIC) of 0.38 μM, the virulent M. tuberculosis strain H37Rv is the target of GSK2200150A's spirocycle core-containing activities [1].
1. GSK2200150A was identified as a representative compound of the GSK Spiros family of anti-tuberculosis (anti-TB) lead compounds through GlaxoSmithKline's high-throughput screening (HTS) campaign against Mycobacterium tuberculosis, and it showed primary anti-TB activity in the initial screening, but the specific in vitro activity parameters (such as minimum inhibitory concentration, MIC) were not described in the literature [1] 2. Novel analogues synthesized based on the structure of GSK2200150A via the oxa-Pictet-Spengler reaction exhibited potency against the virulent strain of Mycobacterium tuberculosis [1] |
| Cell Assay |
In triplicate, GSK2200150A is tested in 96-well microtiter plates at a single concentration of 100 µM or serially diluted in 10 µL of purified H2O. Middlebrook 7H9 complete media, which contains albumin, dextrose, and catalase (ADC), 20% Tween 80, and 50% glycerol, is used to cultivate M. tuberculosis H37Rv. The wells are filled with a 90 µL bacterial suspension with an OD600 nm of 0.001 and incubated for 7 days. Next, add 10 µL of resazurin (0.05% w/v) and incubate for 24 hours at 37°C. Using a FLUOstar Omega microplate reader, measure the fluorescence at 590 nm. The percentage of mycobacterial survival is calculated by subtracting the background fluorescence from each well and comparing the fluorescence of the compound-containing wells to that of the control wells that were not treated with the compound[1].
|
| References | |
| Additional Infomation |
1. Tuberculosis is a global infectious disease affecting about 2 billion people worldwide and causing 1.3 million deaths annually. Clinical anti-tuberculosis drugs mainly rely on drugs developed many years ago. Only one new treatment drug has been approved in the past 40 years. The emergence of drug-resistant strains makes the development of new anti-tuberculosis drugs an urgent need.[1]
2. GlaxoSmithKline (GSK) has disclosed the structure and activity of 177 novel anti-tuberculosis lead compounds (including GSK2200150A), as well as the optimization results of some series of compounds.[1] 3. GSK2200150A is the prototype of the GSK Spiros series of anti-tuberculosis lead compounds. Researchers have synthesized several novel analogs of this family using the oxa-Pictet-Spengler reaction. These analogs have important value in the field of medicinal chemistry.[1] 4. The study of GSK2200150A analogues adopted an open-source approach, with all raw experimental data being fully disclosed to the scientific community in real time [1] |
| Molecular Formula |
C20H23NO3S
|
|---|---|
| Molecular Weight |
357.466524362564
|
| Exact Mass |
357.139
|
| Elemental Analysis |
C, 67.20; H, 6.49; N, 3.92; O, 13.43; S, 8.97
|
| CAS # |
1443138-53-1
|
| PubChem CID |
70689288
|
| Appearance |
Solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
503.4±50.0 °C at 760 mmHg
|
| Flash Point |
258.2±30.1 °C
|
| Vapour Pressure |
0.0±1.3 mmHg at 25°C
|
| Index of Refraction |
1.650
|
| LogP |
4.87
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
25
|
| Complexity |
468
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S1C=CC2=C1CCOC12CCN(CC2C=CC3=C(C=2)OCCO3)CC1
|
| InChi Key |
NCRPMBWORFWNGT-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H23NO3S/c1-2-17-18(23-11-10-22-17)13-15(1)14-21-7-5-20(6-8-21)16-4-12-25-19(16)3-9-24-20/h1-2,4,12-13H,3,5-11,14H2
|
| Chemical Name |
1-[(2,3-Dihydro-1,4-benzodioxin-6-yl)methyl]-6',7'-dihydro-spiro[piperidine-4,4'-[4H]thieno[3,2-c]pyran]
|
| Synonyms |
GSK2200150; GSK-2200150; GSK 2200150; SPIRO; GSK2200150A; GSK-2200150A; GSK 2200150A;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 65 ~71 mg/mL ( 181.83 ~198.61 mM )
Ethanol : ~18 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.17 mg/mL (6.07 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 21.7 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.17 mg/mL (6.07 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 21.7 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.17 mg/mL (6.07 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 10% DMSO+40% PEG300+5% Tween-80+45% Saline: ≥ 2.17 mg/mL (6.07 mM) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7974 mL | 13.9872 mL | 27.9744 mL | |
| 5 mM | 0.5595 mL | 2.7974 mL | 5.5949 mL | |
| 10 mM | 0.2797 mL | 1.3987 mL | 2.7974 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
|
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
